| Literature DB >> 12942122 |
R L M Bekkers1, J Bulten, A Wiersma-van Tilburg, M Mravunac, C P T Schijf, L F A G Massuger, W G V Quint, W J G Melchers.
Abstract
The frequency of high-risk human papillomavirus (hr-HPV) genotypes in patients with adenocarcinoma in situ (ACIS) with coexisting cervical intraepithelial neoplasia (CIN), ACIS without coexisting CIN, and high-grade CIN (CIN II/III) was studied, in order to gain more insight into the relation between hr-HPV infections and the development of coexisting squamous and glandular lesions. The SPF(10) LiPA PCR was used to detect simultaneously 25 different HPV genotypes in biopsies obtained from 90 patients with CIN II/III, 47 patients with ACIS without coexisting CIN, and 49 patients with ACIS and coexisting CIN. hr-HPV was detected in 84 patients (93%) with CIN II/III, 38 patients (81%) with ACIS without CIN, and in 47 patients (96%) with ACIS and coexisting CIN. A total of 13 different hr-HPV genotypes were detected in patients with CIN II/III, and only five in patients with ACIS with/without coexisting CIN. HPV 31, multiple hr-HPV genotypes, and HPV genotypes other than 16, 18, and 45 were significantly more often detected in patients with CIN II/III, while HPV 18 was significantly more often detected in patients with ACIS with/without CIN. There were no significant differences in the frequency of specific hr-HPV genotypes between patients with ACIS with or without coexisting CIN. In conclusion, the frequency of specific hr-HPV genotypes is similar for patients with ACIS without CIN and patients with ACIS and coexisting CIN, but is significantly different for patients with CIN II/III without ACIS. These findings suggest that squamous lesions, coexisting with high-grade glandular lesions, are aetiologically different from squamous lesions without coexisting glandular lesions.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12942122 PMCID: PMC2394485 DOI: 10.1038/sj.bjc.6601204
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Summary of all studies since 1990 with more than 20 ACIS patients in relation with hr-HPV and/or coexisting CIN
| Riethdorf | 42 | 32 | 22 | 10 | ND |
| (76%) | (53%) | (24%) | |||
| Madeleine | 82 | 71 | 32 | 43 | ND |
| (87%) | (39%) | (52%) | |||
| Riethdorf | 33 | 29 | 21 | 8 | 14 |
| (88%) | (64%) | (24%) | (42%) | ||
| Pirog | 23 | 23 | 10 | 6 | 9 |
| (100%) | (43%) | (26%) | (39%) | ||
| Anciaux | 21 | 16 | 6 | 10 | 9 |
| (76%) | (29%) | (47%) | (43%) | ||
| Duggan | 37 | 23 | 8 | 15 | ND |
| (66%) | (23%) | (43%) | |||
| Higgins | 42 | 39 | 13 | 28 | 22 |
| (95%) | (31%) | (67%) | (52%) | ||
| Leary | 30 | 21 | 10 | 11 | 15 |
| (70%) | (33%) | (37%) | (50%) | ||
| Bekkers | 96 | 85 | 39 | 41 | 49 |
| (89%) | (41%) | (43%) | (51%) |
ACIS=adenocarcinoma in situ; hr-HPV= high-risk human papillomavirus; CIN=cervical intraepithelial neoplasia; HPV=human papillomavirus; ND=not documented.
Figure 1Relative frequency of specific hr-HPV genotypes in patients with CIN II/III (90 patients) and patients with ACIS (96 patients). *P<0.05, **P<0.01, ***P<0.001.
Frequency of hr-HPV genotypes in patients with CIN II/III compared with patients with ACIS and coexisting CIN
| 16 | 49 (54%) | 19 (39%) | NS |
| 18 | 7 (8%) | 23 (47%) | |
| 31 | 15 (17%) | 0 (0%) | |
| 45 | 3 (3%) | 5 (10%) | NS |
| Other | 34 (38%) | 2 (4%) | |
| Multiple | 26 (29%) | 2 (4%) | |
| Total hr-HPV positive | 84 (93%) | 47 (96%) | NS |
| hr-HPV negative | 6 (7%) | 2 (4%) | NS |
ACIS=adenocarcinoma in situ; hr-HPV= high-risk human papillomavirus; CIN=cervical intraepithelial neoplasia; NS=not significant.
Frequency of hr-HPV genotypes in patients with ACIS with coexisting CIN compared with patients with ACIS without coexisting CIN
| 16 | 19 (39%) | 20 (43%) | NS |
| 18 | 23 (47%) | 18 (38%) | NS |
| 31 | 0 (0%) | 0 (0%) | NS |
| 45 | 5 (10%) | 2 (4%) | NS |
| Other | 2 (4%) | 1 (2%) | NS |
| Multiple | 2 (4%) | 3 (6%) | NS |
| Total hr-HPV positive | 47 (96%) | 38 (81%) | |
| hr-HPV negative | 2 (4%) | 9 (19%) |
ACIS=adenocarcinoma in situ; hr-HPV= high-risk human papillomavirus; CIN=cervical intraepithelial neoplasia; NS=not significant.